United States : MPI Research, the largest single-site preclinical contract research organization worldwide, was pleased to announce that Tim Derrington is joining MPI Research as President and Chief Operating Officer, effective March 7, 2011.

Derrington brings a wealth of international operational and industry leadership, experience, and specific knowledge for maximizing operational performance, business development, and strategic partnerships. He most recently was Chairman and CEO of Axient Research, a CRO developing clinical research solutions to deliver reliable and accurate patient data to accelerate the development of safe and effective drug and medical treatments.

Prior to Axient, Derrington was the CEO of BioReliance Corp (Invitrogen Corp), a research company providing biologic testing and manufacturing and toxicology services to global pharmaceutical and biopharmaceutical companies that span the product cycle from early preclinical development to licensed production. Over the duration of his career, he has held management positions with Quintiles Transnational Corp (Senior Vice President, Corporate Development); Quintiles Laboratories Worldwide (Chief Operating Officer); Mayo Clinic (Administrative Director-Clinical Trials); and Shell UK Ventures (Managing Director and Project Manager).

Derrington is a graduate of Seale Hayne College, England, and holds an MBA from Henley Management College, Oxfordshire, England.